On February 9, 2010
Amgen Gets More Good Data with Bone Drug Prolia, but Other Risks Await
Amgen’s bone drug Prolia (denosumab) beat a competitor in an important Phase III prostate cancer trial, but investors remained cautious ahead of challenges elsewhere in the pipeline.
No tags for this post.
0 Comments